New drug duo battles tough liver cancer in Head-to-Head trial
NCT ID NCT07152769
Summary
This study is testing whether a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy works better than the current standard immunotherapy (sintilimab) plus the same chemotherapy for people with advanced bile duct cancer inside the liver. It will enroll 104 patients who have not received prior treatment for their advanced cancer. The main goal is to see if the new combination keeps the cancer from growing for a longer period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED INTRAHEPATIC CHOLANGIOCARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, 200062, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.